Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Am J Med. 2018 Nov 29;132(3):354–361. doi: 10.1016/j.amjmed.2018.11.011

Table 3:

Changes in serum urate and allopurinol dosing from the time of index prescription to last follow-up

Variable Usual Care (n = 782) Intervention (n = 681) P-value
Serum Urate
 Final serum urate, mean (SD), mg/dla 7.0 (1.8) 6.8 (1.7) 0.02
 Serum urate change, mean (SD), mg/dla −1.4 (2.0) −1.6 (1.9) 0.06
Allopurinol Dosing
 PDC during year 1, mean (SD)b 0.61 (0.29) 0.68 (0.29) <0.001
 Final allopurinol dose, mean(SD), mg/dl 211 (106) 237 (107) <0.001
Final allopurinol dose, mg/day, %
 <100 0.5 0.6 <0.001
 100 to <200 38.6 26.6
 200 to <300 18.3 21.4
 300 39.3 44.9
 >300 3.3 6.5
Allopurinol dose change, % <0.001
 No change 79.3 63.4
 Increase 18.0 33.0
 Decrease 2.7 3.5
a

No follow-up serum urate available for 117 (15%) usual care patients and 83 (12%) intervention patients; either baseline or follow-up (needed to calculate change) were missing in 239 (31%) usual care patients and 211 (31%) intervention patients; mean (SD) interval between laboratory measures was significantly shorter among intervention patients (249 ± 263 vs. 372 ± 274 days; p<0.001)

b

PDC = proportion of days covered